UA93217C2 - Compounds with medicinal effects due to interaction with the glucocorticoid receptor - Google Patents
Compounds with medicinal effects due to interaction with the glucocorticoid receptorInfo
- Publication number
- UA93217C2 UA93217C2 UAA200807041A UAA200807041A UA93217C2 UA 93217 C2 UA93217 C2 UA 93217C2 UA A200807041 A UAA200807041 A UA A200807041A UA A200807041 A UAA200807041 A UA A200807041A UA 93217 C2 UA93217 C2 UA 93217C2
- Authority
- UA
- Ukraine
- Prior art keywords
- optionally halogenated
- alkoxy
- alkyl
- hydrogen
- halogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 title 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 title 1
- 230000003993 interaction Effects 0.000 title 1
- 230000007721 medicinal effect Effects 0.000 title 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 229940117965 Glucocorticoid receptor modulator Drugs 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- -1 hydroxylmethyl Chemical group 0.000 abstract 1
- 229910052757 nitrogen Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides for compounds having the structure according to the formula I wherein: X is a carbon or nitrogen atom; Ar is phenyl or heteroaromatic ring; Ris hydrogen, halogen, CN or (1C-)alkyl; Ris hydrogen, halogen or optionally fluorinated (1C-)alkoxy; Rand Rare independently hydrogen, optionally halogenated (1C-)alkyl, optionally halogenated (1 C-)alkoxy, optionally halogenated aryl(1C-)alkoxy, optionally halogenated (1C-)alkenyl or hydroxylmethyl; Ris hydrogen, halogen, optionally halogenated (1C-)alkoxy or optionally halogenated aryl(1C-)alkoxy; Ris hydrogen, benzyl, optionally substituted with one or more halogens or (1C-)alkyl, or Ris optionally halogenated (1C-)alkyl; each Rindependently is hydrogen, halogen, optionally halogenated (1C-)alkyl or optionally halogenated (1C-)alkoxy and pharmaceutically suitable acid addition salts thereof for use as glucocorticoid receptor modulators, in particular for treatment of central nervous system disorders., (I)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75256205P | 2005-12-21 | 2005-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA93217C2 true UA93217C2 (en) | 2011-01-25 |
Family
ID=50829850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200807041A UA93217C2 (en) | 2005-12-21 | 2006-12-18 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA93217C2 (en) |
-
2006
- 2006-12-18 UA UAA200807041A patent/UA93217C2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP1822A (en) | Substituted pyridinones as modulators of P38 MAP kinase. | |
| UA100132C2 (en) | Isoxazolo-pyridine derivatives | |
| ATE453639T1 (en) | PHENYL SUBSTITUTED PYRIMIDINE COMPOUNDS FOR USE AS KINASE INHIBITORS | |
| NZ504336A (en) | Tetrahydrofuran substituted adenosine A1 receptor agonists, pharmaceuticals thereof, and their use as medicaments | |
| SE0104334D0 (en) | Therapeutic agents | |
| TW200517109A (en) | Substituted pyridinones | |
| TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
| TW200508180A (en) | Therapeutic agents | |
| BG108650A (en) | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | |
| DK1697371T3 (en) | Azabicyclic heterocyclic compounds as cannabinoid receptor modulators | |
| MXPA06009475A (en) | Quinazoline derivatives and therapeutic use thereof. | |
| RU2008100019A (en) | METHOD FOR TREATING AN EXTRAORDINAL DAYS OF Drowsiness (OPTIONS) | |
| MY146599A (en) | New azetidine compounds | |
| PH12013501895A1 (en) | Ethynyl derivatives as positive allosteric modulators of the mglur5 | |
| MY148504A (en) | Compounds which have activity at m? receptor and their uses in medicine | |
| NO20082436L (en) | Compounds with medical effects due to the interaction with glucocorticoid receptor | |
| NO20064238L (en) | Imidazoline derivatives with CB1 agonist activity | |
| MY133370A (en) | Carbamate compounds for use in preventing or treating bipolar disorders | |
| IL157588A (en) | Carbamate compounds for use in preventing or treating psychotic disorders | |
| UA93217C2 (en) | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | |
| SI1645558T1 (en) | Piperazinylpyrazines as serotonin 5-HT2C receptor modulators | |
| TW200628437A (en) | Aminoindane dopamine D3 receptor antagonists | |
| SE0403118D0 (en) | New compounds 2 | |
| MX2010004832A (en) | Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor. | |
| TW200626571A (en) | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |